| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics |
Pharmaceutical Research Institute, Oncology Drug Discovery, Bristol-Myers Squibb Company, Inc., Princeton, New Jersey 08543
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
|
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Although it would be desirable to develop therapeutic agents that specifically target oncogenic Ras activity, such compounds have not been identified despite concerted efforts over the past decade. The search for inhibitors of Ras function has intensified in the past 11 years after the discovery that Ras proteins are among the limited set of known proteins that undergo farnesylation. Farnesylation of Ras proteins is required for their membrane association, which in turn is critical for their biological functions. When farnesylation is blocked, the function of Ras proteins is severely impaired because of the inability of the nonfarnesylated protein to anchor to the membrane (9, 10, 11) . Therefore, FT,2 the enzyme that catalyzes the farnesylation reaction, has become an important target for the design of novel anticancer agents (12, 13, 14, 15, 16, 17, 18) .
Although early studies indicated that FTIs do selectively affect the growth of Ras-transformed cells and exhibit antitumor activity in preclinical animal models (19, 20, 21, 22, 23, 24, 25) , evolving recent studies portray a highly complex nature to the biology and preclinical antitumor activity of FTIs (26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36) . In FTI-treated cells, K-Ras and N-Ras proteins have been shown to undergo geranylgeranylation (37 , 38) catalyzed by GGTI and potentially remain functional. However, FTIs, in general, demonstrate in vitro and in vivo activity against tumor cells bearing K-Ras mutations (23 , 39, 40, 41) . Moreover, no clear correlation between Ras mutation status and FTI sensitivity has been observed by several investigators (23 , 39, 40, 41) . Whereas some investigators effort championed RhoB and centromere-associated CENP-E and CENP-F as the molecular targets of FTIs in all or some tumor cells, there remains no consensus as to the relevant target(s) of FTIs that can explain the mosaic pharmacology of FTIs (42, 43, 44, 45, 46, 47, 48) .
BMS-214662, an imidazole-containing tetrahydrobenzodiazepine, is a non-thiol, non-peptide small molecule inhibitor (49) . The present report describes the pharmacology of BMS-214662 and its broad spectrum antitumor activity against a variety of human tumor xenografts. Its broad spectrum antitumor activity, by both parenteral and oral routes of administration, was found to be of sufficient magnitude to provide the basis of further development toward clinical trials.
|
MATERIALS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Farnesyltransferase.
A pAcUW31-based baculovirus transfer vector, pML88, encoding both the 
and ß subunits of hFT, was constructed. After cotransfection of pML88 and wild-type baculovirus DNA into insect cells, recombinant baculoviruses were isolated, purified, and analyzed for their ability to overexpress biologically active hFT. High levels of hFT were produced in cells infected with pML88 recombinant baculovirus for 48 h. A majority of the hFT was recovered in the soluble fraction and was purified to 
95% purity by DE-52 and Phenyl Superose chromatography steps.
GGTI.
A baculovirus expression construct containing the subunit of hFT was coinfected into High Five insect cells with a baculovirus expression construct coding for the ß subunit of human GGTI. After sonication, hGGTI was purified from the insect cell supernatant by DE-52 and Phenyl Superose chromatography steps. The purified enzyme was estimated to be at least 80% pure.
Cell Lines and Culture.
KNIH, Rat1CVLS, Ras-GG, myr-Ras, and K-Ras4B cells have been described previously (25)
. RC-165 cells are Rat1 cells transformed by human genomic K-Ras4B DNA (contains the human K-ras4B minigene with a G418 selectable marker with cys12 mutation). v-Raf cells are NIH 3T3 cells transformed by a recombinant clone carrying gag v-Raf and neoR in an MSV vector (50)
. c-Raf cells are NIH 3T3 cells transformed by activated c-Raf (22W mutant) and were described earlier (51)
. MEK2 cells are Rat1 cells transformed by human MEK-1 cDNA with two activating mutations, one at codon 218 (serine to aspartate) and the other at codon 222 (serine to aspartate). The cell line panel was composed of: human ovarian carcinomas (A2780/DDP-S, A2780/DDP-R, A2780/TAX-S, A2780/TAX-R, and OVCAR-3); human breast carcinomas (MCF-7 and SKBR-3); human prostate carcinomas (LNCAP and PC-3); human colon carcinomas (HCT-116, HCT-116/VM46, HCT-116/VP35, Caco-2, LS 174T, and MIP); human lung carcinomas (A549 and LX-1); a human squamous cell carcinoma (A431); human leukemias (CCRF-CEM, HL-60, and K562); ABAE cell line; a mouse lung carcinoma (M109); and a p53-/- mouse lung fibroblast cell line, MLF, isolated from p53 knockout mice. The HCT-116/VM46 cell line is a MDR variant of the parental HCT-116 cells and overexpresses P-glycoprotein (52)
. The HCT-116/VP35 cell line is a variant that has low topoisomerase II levels and is resistant to etoposide (52)
. The A2780/DDP-R cell line is resistant to cisplatin relative to the parental A2780/DDP-S cells. A tubulin mutation is present in the A2780/TAX-R cells, which are resistant to paclitaxel relative to the parental A2780/TAX-S cells (both provided by Dr. Tito Fojo, National Cancer Institute, Bethesda, MD; Ref. 53
).
Rat1CVLS, RC-165, K-Ras4B, Myristoyl-Ras, and GG-Ras cells were grown in DMEM with 110 mg/l sodium pyruvate supplemented with 10% FBS (Colorado Serum Co.; not heat inactivated) in a 95% humidified CO2 (6–7%) incubator maintained at 37°C. All other rodent cells were grown in DMEM high glucose supplemented with 5% calf serum (Colorado Serum Co.). Mammalian cells were maintained in logarithmic growth in RPMI 1640 (Life Technologies, Inc.), 5 mM HEPES buffer, and 10% fetal bovine serum (Life Technologies, Inc.) and were passed once per week. ABAE cells (a primary cell line) were grown in RPMI 1640 containing 2.0 ng/ml of basic fibroblast growth factor.
Mice.
BALB/c background athymic (nude) female mice and C57BL/6 and (C57BL/6 x DBA/2)F1 conventional mice, all 
5 weeks of age, were purchased from Harlan Sprague Dawley (Indianapolis, IN). They were provided with food and water ad libitum. All studies involving these animals were conducted in accordance with NIH and our BMS animal care and use guidelines.
Tumors.
The following human tumor lines were used: HCT-116 colon, HCT-116/VM46 colon, Calu-1 lung, EJ-1 bladder, MiaPaCa-2 pancreatic, N-87 gastric, and HT-29 colon carcinomas. Two murine tumor models, LL carcinoma and M5076 sarcoma, were also used. The human tumors were passaged s.c. in vivo at approximately 2–3-week intervals. The murine tumors were passaged s.c. in C57Bl/6 mice at 2-week intervals. The following Ras mutations are known to exist and were confirmed at BMS in these tumors: HCT-116 and the HCT-116/VM46 subline (K-Ras); Calu-1 (K-Ras); EJ-1 (H-Ras); MiaPaCa-2 (K-Ras); HT-29 (none); LL (none); and M5076 (none).
Pharmacology Assays.
The assays for prenyltransferase, reversion, SAG, and H-Ras processing inhibition were carried out as described earlier (18
, 25)
. Apoptosis was measured using the cell death detection ELISAplus kit (nucleosomal DNA ELISA assay) supplied by Boehringer Mannheim and Apo-direct flow cytometry kit (TUNEL assay) supplied by Pharmingen. The instructions supplied by the kit manufacturer were followed.
In Vitro Cytotoxicity Assay.
In vitro cytotoxicity was assessed by a vital dye assay using a tetrazolium salt, MTS. Cells were seeded in 96-well microtiter plates, and 24 h later, BMS-214662 was added at various concentrations. The cells were incubated at 37°C for 72 h, at which time MTS in combination with phenazine methosulfate was added. After an additional 3 h, the absorbancy was measured at 492 nm, and the growth inhibition results were eventually expressed as IC50s.
The IC50s for BMS-214662 were calculated and expressed graphically as a mean bar graph on a log scale for each cell line exposed to the compound. A geometric mean of the log IC50s was also determined. The difference between the mean log IC50 and each individual cell line’s log IC50 was calculated and plotted in a mean bar graph. Bars that project to the right represent cells that are more sensitive than the mean IC50 for all of the cell lines. Bars that project to the left represent cell lines that are less sensitive (more resistant) than the mean.
Efficacy Testing.
Briefly, (C57BL/6xDBA/2)F1 mice were implanted s.c. with tumor fragments (M5076 and LL), and treatments began 1 day after tumor implant. Treatments were administered either i.v. or i.p. The specific treatments evaluated are described in "Results." For human tumor xenograft tests, nude mice were implanted s.c., and treatments (p.o., i.v., or i.p.) were begun when sufficient mice bearing tumors of a predetermined size were distributed into various control and treatment groups. The "predetermined size" initially was typically 100 mg, but the stringency of test conditions eventually increased, and many experiments (specifically described) involved the use of larger, 200–400 mg tumors. Treatments involving various schedules were used, and they are described in "Results."
Assessment of antitumor effectiveness was made by determining the relative median times for control (C) and treated (T) mice to grow tumors to a target size. The target size was 1 g for M5076 and LL and 400–500 mg for all of the human tumor models. The delay in tumor growth (T - C, days) was converted to gross LCK values by taking into account the tumor volume doubling times of control groups in each individual experiment. A LCK of 1 or better was considered an active result. Cures were also used to assess activity. A mouse was considered cured when no mass <35 mg was present at the site of tumor implant after a number of days after treatment had elapsed equivalent to >10 tumor volume doubling times in that experiment. Therapeutic results were reported at the optimal dose, and results were not used if more than one death occurred in the treated group. A MTD, although often synonymous with the optimal dose, is defined as a dose immediately below that causing unacceptable toxicity (i.e., more than one death), or in the absence of any deaths, was assumed when accompanied by >20% body weight loss. There were typically seven to eight mice per treatment and control groups.
i.v. Infusion of Mice.
Infusional i.v. drug delivery via the tail vein was accomplished using the L-CATH Neonatal Catheter System (Luther Medical Products, Inc., Tustin, CA). The 28-gauge (0.4-mm outside diameter) catheter was inserted in the tail vein 5 cm from the base and advanced 4 cm into the vein. The catheter was stabilized with Nexaband Liquid (Henry Schein, Inc.) and then firmly secured with Tegaderm (Henry Schein, Inc.). The entire tail and catheter were then inserted into a protective sheath, and then the mice were tied to a swivel. Mice were moving freely during the entire infusion period.
In Vivo-in Vitro Tumor Excision Clonogenic Cell Survival Assay.
After 24-h drug infusions of varying doses, tumors were excised from mice, minced with scissors, and dissociated using an enzyme mixture consisting of 0.025% collagenase (Sigma Chemical Co., St. Louis, MO), 0.05% Pronase (Calbiochem, La Jolla, CA), and 0.04% DNase (Sigma Chemical Co.) for 1 h at 37°C. After removal of debris, by passing the tumor suspensions through 70-µm nylon screens, the cells were washed in PBS, counted, and plated at specified numbers for determination of colony formation capacity.
Apoptosis in Tumors.
Mice (n = two to three/group) implanted with HCT-116 xenografts were administered a single dose of BMS-214662 at 250 mg/kg i.v., 300 mg/kg i.p., or 400 mg/kg p.o. An additional group (n = 2) received 400 mg/kg BMS-214662 daily for 2 days (administered p.o. on day 1 and i.p. on day 2). Nontreated mice (n = 4) with time-matched HCT-116 tumors served as controls. Tumors were collected at 24 h after dose, processed following standard methods, sectioned, and stained with H&E. Serial sections of each tumor were processed for in situ apoptotic cell labeling by the TUNEL method (ApoTag; Oncor).
AIs of the tumor, defined as the percentage of apoptotic tumor, was reported previously (54) . Apoptotic tumor cells were identified by light microscopy based on positive TUNEL staining and/or defined morphological criteria (55) . For each tumor, 10–30 random fields, which excluded necrotic areas, were evaluated at x200, and the total number of tumor cells and apoptotic cells were enumerated per field. AIs were calculated by dividing the total number of apoptotic tumor cells by the total cell population x 100. Mean AIs were calculated for each group.
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
. BMS-214662 is a potent inhibitor of human FT as assayed in vitro using H-Ras or K-Ras as the farnesyl acceptor substrates. The FT inhibitory potency versus H-Ras and K-Ras were determined in several independent experiments, and the results are summarized in Table 1
. The mean IC50 and IC90 (50 and 90% inhibitory concentrations) for H-Ras farnesylation were determined to be 1.3 and 18 nM, respectively. BMS-214662 inhibited H-Ras farnesylation more potently than K-Ras farnesylation (IC50, 1.3 nM for H-Ras versus 8.4 nM for K-Ras).
|
|
. Thus, BMS-214662 is >1000-fold selective for hFT over human hGGTI.
Activity Spectrum of BMS-214662 in Cells
Reversion and SAG.
Two cell-based assays, the reversion assay and the SAG assay, were used primarily for evaluating the cell activity of BMS-214662. Both assays measure the response of cells because oncogenic Ras function is impaired due to FT inhibition. BMS-214662 reverts H-Ras-transformed Rat1 cells to a normal flat monolayer phenotype in cell cultures at low micromolar concentrations. Near complete reversion occurred when cells were exposed for 72 h at 0.3 µM BMS-214662 (Table 2)
. The transformed properties of H-Ras proteins that have been engineered to function independently of farnesylation such as N-myristoyl Ras (MyrRas) or geranylgeranyl Ras (RasGG) are not affected by BMS-214662 (no reversion at 2.5 µM), suggesting Ras farnesylation as the specific target. In addition, the transformed properties of v-Raf or MEK, which function downstream of Ras, are also not affected, thus confirming the specificity of BMS-214662 (Table 2)
. BMS-214662 failed to revert the K-Ras-transformed cells (KNIH, RC-165, and K-Ras4B val12) phenotype.
|
. K-Ras-transformed rodent cells, MIP human colon tumor cells, and MiaPaCa-2 human pancreatic tumor cells require 0.6 µM for complete inhibition. MEK-2-transformed cells are not dependent on Ras function for SAG and are not affected by BMS-214662 at concentrations up to 2.5 µM.
Inhibition of H-Ras Processing in H-Ras-transformed Rodent Cells.
To demonstrate that BMS-214662 inhibits Ras processing in cells and causes cytoplasmic localization of unmodified Ras proteins, we used H-Ras-transformed Rat1 CVLS cells. Cells were treated for 48 or 72 h with 0.1 or 0.5 µM BMS-214662. Total cellular extracts were prepared and fractionated into soluble (S100) and particulate (P100) fractions. The Ras proteins in S100 and P100 fractions were immunoprecipitated with agarose-linked Y13-259 anti-Ras antibody, analyzed by SDS-PAGE, transferred to Immobilon-P membrane, and probed with H-Ras-specific antibody 146-03E4. The results, shown in Fig. 2A
, indicate that a majority of Ras proteins were present in the particulate fraction in the untreated cells. After treatment with BMS-214662, Ras proteins localized to the soluble fraction, and this process occurred in a dose-dependent manner. Concentrations as low as 100 nM caused partial inhibition of Ras processing (as reflected in the shift to soluble fraction) in 48 h. Near complete depletion of H-Ras from the membrane fraction occurred at 500 nM. On the basis of results from several experiments, we conclude that complete inhibition of H-Ras processing in Rat1 CVLS cells requires 48–72 h of drug treatment.
|
. In contrast to kinetics in Rat1 CVLS fibroblasts, the kinetics of disappearance of membrane-bound Ras were nearly complete in 24 h with as little as 100 nM BMS-214662. These results suggest that the turnover of membrane-bound farnesylated Ras may vary in different cell types and are consistent with various (6 and 20 h) half-lives reported for Ras proteins (56
, 57) .
Lack of Inhibition of K-Ras Processing in HCT-116 Human Colon Tumor Cells.
Previous studies by others (37
, 38
, 58)
showed that K-Ras and N-Ras proteins in rodent fibroblasts or human tumor cells are resistant to treatment with potent FT inhibitors. The K-Ras and N-Ras proteins remained associated with membranes, although H-Ras proteins were localized to the cytosolic fraction during FTI treatment. Similarly, BMS-214662 failed to cause cytoplasmic localization of K-Ras proteins in HCT-116 cells. Treatment of cells with concentrations as high as 25 µM for 24 h did not alter the amount of K-Ras proteins in the membranes, and there was no apparent increase in the amount of soluble (cytosolic) K-Ras proteins (Fig. 2C)
. These results are consistent with BMS-214662 being highly specific for FT over GGTI and the apparent ability of GGTI to geranylgeranylate K-Ras proteins when FT is inhibited in cells (37
, 38
, 58)
.
Cytotoxicity of BMS-214662.
The FT inhibitory potencies and cell activities of tetrahydrobenzodiazepine FTIs and many other classes of FTIs are comparable (20
, 23, 24, 25
, 40
, 41
, 49)
. In many cell types, low µM concentrations of these inhibitors block Ras farnesylation to near completion. Although many of these other classes, in particular tetrapeptide-based inhibitors, are known to be nontoxic at high µM concentrations, the tetrahydrobenzodiazepine inhibitors including BMS-214662, are toxic to cells at 2–10 µM concentrations. Cytotoxicity seems to be unrelated to complete inhibition of Ras processing and signaling, because BMS-214662 displayed toxicity to H-Ras, H-RasCVLL, and MyrH-Ras transformed Rat1 cells at similar concentrations. In the latter cells, Ras functions independently of farnesylation, and therefore FTIs should be nontoxic if toxicity is attributable predominantly to Ras inhibition per se. Similar observations were made with c-Raf, v-Raf, and MEK-2 transformed cells, which are Ras independent. Although these results do not eliminate the possibility that FT inhibition and/or processing of other farnesylated proteins is related to toxicity, it is unlikely attributable to inhibition of Ras farnesylation alone.
Toxicity Is Attributable to BMS-214662-induced Apoptosis in HCT-116 Human Colon Tumor Cells.
In general, BMS-214662-induced toxicity was observed in cells exposed for a duration >24 h. To determine whether the toxicity was a result of apoptosis induction, HCT-116 human colon cells were exposed to the drug for the first 2 h, or 48 h of a 48-h incubation period, and apoptosis was determined by nucleosomal DNA ELISA assay. BMS-214662 caused an increase in nucleosomal DNA in the cytoplasm of cells without an increase in the medium (a marker for apoptosis). Although short drug exposure did lead to apoptosis, it required low micromolar concentrations (Fig. 3A)
. Drug exposure for 48 h resulted in apoptosis with submicromolar concentrations. These results suggest that drug exposures as short as 2 h prime HCT-116 cells to undergo apoptosis in 48 h.
|
. We next determined the time kinetics of apoptosis. HCT-116 cells were exposed to BMS-214662 for various periods of time, and apoptosis was immediately measured by the nucleosomal DNA ELISA assay. No detectable apoptosis, irrespective of the high drug concentration, occurred in the first 6 h (data not shown). Apoptosis was readily observed at 24 h with as little as 0.37 µM BMS-214662. The minimal concentrations required for apoptosis did not differ appreciably for 24 and 48 h, suggesting a requirement for a certain threshold drug concentration. These results also suggest that the molecular events unleashed by BMS-214662 require a 24-h period to manifest in the form of apoptosis.
Cell Cycle Analysis.
The effect of BMS-214662 on the cell cycle distribution and induction of apoptosis in HCT-116 cells was analyzed by flow cytometry. HCT-116 cells were exposed to compounds for 24 h and processed for cell cycle analysis with propidium iodide, and AI was determined by the TUNEL assay. BMS-214662-induced apoptosis was detectable at 0.5 µM, with a majority of the apoptotic cells coming from the G1 and S-phase cells (Fig. 4A)
. The number of apoptotic cells increased to 20% of the population at 25 µM. A similar experiment performed with murine M109 lung tumor cells showed no increase in apoptotic cells at 25 µM BMS-214662 (Fig. 4B)
.
|
Cytotoxicity against Tumor Cell Line Panel.
Consistent with its potent apoptotic activity, BMS-214662 demonstrated potent in vitro cytotoxicity against a cell line panel consisting of human tumors, as well as mouse tumor and fibroblast cells and bovine normal endothelial cells. The data shown in Fig. 5
are expressed as IC50s for each cell line in a bar graph. The mean IC50 was 0.20 µM. The individual IC50s and the mean bar graph pattern illustrate that BMS-214662 has robust cell selectivity against a wide variety of tumor cell types. There was a >32-fold difference between the most sensitive and most resistant cell lines.
|
HCT-116/VM46 and MIP colon cells both overexpress P-glycoprotein, a drug efflux pump, and are resistant to a number of lipophilic anticancer agents, such as paclitaxel, etoposide, and doxorubicin. The HCT-116/VM46 cells were 4-fold resistant to BMS-214662 relative to the parental HCT-116 cells, and MIP cells were 2-fold resistant relative to the mean IC50 for all cell lines in the panel. These results suggest that BMS-214662 may be a weak substrate for P-glycoprotein.
In Vivo Activity
BMS-214662 versus HCT-116 Human Colon Carcinoma.
The initial discovery of antitumor activity associated with BMS-214662 was made after its oral administration, once qd for 10 days (x10), Monday through Friday only, to mice bearing s.c. HCT-116 human colon tumors that ranged in size from 80 to 136 mg. Optimal treatment with the highest dose evaluated, 600 mg/kg/administration, which showed no evidence of being an MTD, cured eight of eight mice. Even the next lower dose tested, 300 mg/kg/administration, cured four of eight mice. A summary of this and other optimal antitumor effects is shown in Table 3
.
|
BMS-214662 versus Calu-1 Human Lung Carcinoma.
Additional antitumor testing with p.o.-administered BMS-214662 was carried out using the human lung carcinoma, Calu-1. The highest dose administered was escalated to 800 mg/kg/administration for 14 days (Monday–Friday), against tumors staged to a large average weight of about 250 mg (day 21 after tumor implant). At this maximum dose, BMS-214662 cured four of eight mice. The next lower dose, 500 mg/kg/administration, was effective (3.2 LCK) but not curative, and the next lower dose, 300 mg/kg/administration, was minimally active (1.2 LCK). This dose-response is illustrated in Fig. 6
.
|
. The next lower dose, 300 mg/kg/administration, cured three of eight mice, and the lowest dose tested, 200 mg/kg/administration, was also effective (1.5 LCK).
|
An additional EJ-1 experiment was used to characterize the i.v. antitumor activity of BMS-214662. The compound was formulated in 5% Tween 80 in water for i.v. administration. The sizes of the tumors at initiation of therapy were also larger (160–343 mg) than those used in the initial EJ-1 experiment. At the highest dose tested, 175 mg/kg/administration, six of seven mice were cured. The next lower dose tested, 125 mg/kg/administration, cured five of eight mice.
BMS-214662 versus HCT-116/VM46 Human Colon Carcinoma.
An experiment was conducted in mice bearing HCT-116/VM46 to determine the efficacy of BMS-214662 against MDR tumors. The optimal effect produced after p.o. administration of 600 mg/kg/administration, qdx10 (Monday–Friday), of BMS-214662 was 2.0 LCK accompanied by three of seven cures.
BMS-214662 versus MiaPaCa-2 Human Pancreatic Carcinoma.
MiaPaCa-2 was staged to 104–188 mg at the time of treatment initiation. BMS-214662 was given p.o., qdx10 (Monday–Friday). At the highest dose evaluated, 600 mg/kg/administration, the compound was active, curing four of seven mice.
BMS-214662 versus N-87 Human Gastric Carcinoma.
Mice bearing N-87 tumors were treated twice daily for 14 days, p.o., with BMS-214662 beginning on day 23 after tumor implant. At the highest dose tested, 300 mg/kg/administration, 0.9 LCK was produced with no cures.
BMS-214662 versus Murine Tumors.
Two murine tumor models, LL and M5076 sarcoma, were also used to evaluate the therapeutic potential of BMS-214662. Against unstaged LL, i.p. treatment with BMS-214662, q2dx5, failed to demonstrate any activity (0 LCK) at doses as great as 400 mg/kg/administration (i.e., well within the active range of doses as seen in the human tumor models). Against unstaged M5076, BMS-214662 was evaluated in two different vehicles, 5% Tween 80 and 10% ethanol (both in water diluents). The compound in 5% Tween 80 was administered i.v. on a q2dx5 schedule at doses as great as 200 mg/kg/administration. BMS-214662 in 10% ethanol was administered i.p., q4dx3, and reached the MTD at 300 mg/kg/administration. BMS-214662 was inactive (0 LCK) versus M5076 by both routes of administration.
Schedule Dependency/Optimization.
The antitumor activity of BMS-214662 was found to be schedule independent but was cumulatively dose dependent. BMS-214662 was evaluated i.p. and p.o. against staged Calu-1 using different treatment schedules of identical duration in an attempt to discern an optimal treatment schedule or schedule dependency. All treatments began 20 days after tumor implant. Selected data from that experiment are summarized in Table 4
.
|
Direct Cytotoxicity against Tumor Cells in Vivo.
Nude mice bearing the human carcinomas HCT-116 or EJ-1 were treated with BMS-214662 by i.v. infusion at various doses. At the end of treatment, tumors were excised, and tumor cell kill was determined by an in vitro colony formation assay. As shown in Fig. 8
, BMS-214662 was significantly cytotoxic to both HCT-116 and EJ-1 tumor cells; the doses of BMS-214662 required to kill 90% of clonogenic tumor cells were approximately 75 and 100 mg/kg for HCT-116 and EJ-1 tumors, respectively.
|
. Mean AIs from each group are presented in Table 5
. The AIs in HCT-116 tumors were increased 4–10-fold in BMS-214662-treated mice as compared with nontreated controls. Highest AIs were observed in tumors from mice treated at 300 mg/kg or higher. These results, based on a limited sample size, indicate that tumor cell apoptosis is induced after BMS-214662 administration.
|
|
When the status of H-Ras processing the same tumor samples was analyzed, there was partial depletion of Ras in the particulate fraction and rapid accumulation of unprocessed Ras in the soluble fraction in tumors treated for 6 h; the depletion of Ras in the particulate fraction was near complete by 24 h (Fig. 10)
. These results establish the pharmacological inhibition of FT and the resultant block in H-Ras processing in tumor xenografts treated with BMS-214662.
|
|
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Our studies on the effect of BMS-214662 on morphological reversion with various cell lines imply H-Ras as the specific target. However, studies by others (32 , 60) suggest that the morphological reversion of transformed cells caused by FTIs such as B581 and L-739,749 was independent of Ras function and was proposed to involve interference with RhoB activity. The FTIs used in these studies belong to distinct chemical classes but are potent and seemingly selective FTIs. Thus, although the basis for the differences between our results and those of others (32 , 60) is not clear at present, these differences suggest that not all FTIs (belonging to different chemical classes) produce the same effects in cells. Despite its controversial nature (whether Ras or other protein involvement), our experience has been that the morphological reversion assay is a good measure of FT inhibition in cells and has been widely used for determining the whole cell activity of FTIs.
BMS-214662 inhibited the anchorage-independent growth of H-Ras- and K-Ras-transformed rodent fibroblasts but not MEK2-transformed rodent cells. H-Ras-transformed cells are 10-fold more sensitive than K-Ras-transformed cells (IC50, 0.025 versus 0.3 µM). The low sensitivity of K-Ras cells to BMS-214662 is consistent with an order of magnitude higher affinity of FT for K-Ras compared with the H-Ras proteins (59) and K-Ras geranylgeranylation in FTI-treated cells (37 , 38) . MEK2-transformed cells are not dependent on Ras function for SAG and are not significantly affected by BMS-214662. Thus, the effects of BMS-214662, particularly at low concentrations, in rodent cell models is consistent with Ras as the specific target.
BMS-214662 inhibited the SAG of human tumor cells, which usually contain multiple genetic aberrations, such as mutant Ras, mutant p53, up-regulated protein tyrosine kinase receptors, cell cycle alterations, and deregulated Myc expression. In addition, BMS-214662 targeted human tumor cells with or without Ras mutation and independent of K-Ras or H-Ras mutation. Similar conclusions were drawn by others using FTIs B581 and L-744,832 (23 , 39) . Overall, these results raise questions about Ras being the target for FTIs, and there is additional evidence that disconnects Ras, such as lack of correlation of Ras mutation with cytotoxic activity (see later).
BMS-214662 is one of the most potent of our tetrahydrobenzodiazepine FTIs in inducing apoptosis in HCT-116 human colon tumor cells. As brief an exposure as 2 h to 3 µM BMS-214662 primes HCT-116 cells to eventually undergo apoptosis within 48 h, and longer exposures require relatively lower concentrations. Continuous exposure for 24–48 h resulted in apoptosis at 0.1–0.3 µM BMS-214662, concentrations that are easily attainable in animals without undue toxicity. Although the observation that FTIs or agents that block isoprenylation of proteins by indirect mechanisms induce apoptosis in Ras-transformed rodent fibroblasts and in human tumor cells has been reported widely by others (31 , 34 , 61, 62, 63, 64, 65, 66, 67) , apoptosis was observed either in specialized conditions (low serum or cell adhesion prevention) or with high micromolar concentrations. In contrast, BMS-214662 induced apoptosis at submicromolar concentrations in regular tissue culture medium with 10% serum. It is not clear at present whether and how BMS-214662-induced apoptosis differs from apoptosis reported for other FTIs. In our experience, induction of apoptosis as reported here appears to be specific to the potent tetrahydrobenzodiazepine FTIs because other classes of inhibitors (phosphonate bisubstrate, thiol tetrapeptide, imidazolyl tetrapeptide, thioproline tetrapeptide, thiol piperazine, thioproline piperazine, thiol aminobenzoate, thiol dipeptide, thioproline dipeptide, and GGTI-specific tetrapeptide) did not induce significant apoptosis or caused only mild apoptosis/necrosis at very high concentrations (50–200 µM). Most of these compounds are roughly equipotent to the tetrahydrobenzodiazepine inhibitors in FT or cell reversion assays.
The high apoptotic potency of BMS-214662 prompted us to analyze the cytotoxic activity against a large panel of cell lines using the MTS assay. BMS-214662 is a potent cytotoxic agent in vitro against a wide variety of human tumor cell lines, including colon, breast, ovarian, prostate, and squamous cell carcinomas. Two mouse cell lines in the panel, a fibroblast and a carcinoma, were both relatively resistant to BMS-214662 when compared with most of the human carcinoma and human fibroblast cell lines. Although the murine sample size was limited, the possibility of a species difference in sensitivity remains possible.
Among the more sensitive cell lines (IC50 less than the mean; Fig. 5
) were those lacking ras mutations (A431 and OVCAR-3) and with ras mutations (HCT-116, LS174T, and CCRF-CEM). Less sensitive cell lines that contained a mutated ras include LX-1, MIP, A549, and M109. This lack of correlation between Ras mutation status and sensitivity has been widely reported for a variety of FTIs (39, 40, 41
, 68)
, and it has been hypothesized that the antitumor effects of FTIs involve inhibition of farnesylation of proteins other than Ras (15
, 27
, 42
, 43)
. Although no single candidate protein has emerged as the true FTI target to date, interesting candidates include RhoB, RhoE, PRL-1 tyrosine phosphatases, centromere-associated CENP-E/F, nuclear lamins, and IP3 phosphatase (15
, 42)
. The "FTI-Rho hypothesis" put forward by the Prendergast group has been supported by compelling evidence for FTI altering Rho-dependent cell adhesion, survival, and apoptosis signals (27, 28, 29, 30, 31, 32, 33
, 69)
. However, data depicting RhoB as a tumor suppressor (70)
and the apparent lack of correlation between RhoB expression and FTI sensitivity in tumor cell lines (42)
imply that the true target(s) of FTI remains to be identified. We also observed minimal resistance of MDR-containing cell lines toward BMS-214662, suggesting that our FTI, at best, may be a weak MDR substrate. One other FTI, SCH 66336, was reported recently to be a potent inhibitor of the MDR1 pump (71)
.
BMS-214662 was found to possess broad spectrum antitumor activity in human tumor xenografts of diverse histological sources. Curative activity against well-established tumors was demonstrated parenterally and p.o., regardless of the presence or absence of ras mutations in the responding tumor lines. Our results are consistent with several published reports on FTI antitumor activity being independent of activated ras oncogene (21 , 23 , 40 , 41 , 68 , 72) . BMS-214662 sharply differs from other FTIs in terms of its potent tumor regression and curative potential. Other FTIs such as SCH66336, L-744,832, R115777, BIM-46228, FTI-277, B-956, and FTI-2153 primarily act as cytostatic drugs and produce noncurative regressions in transgenic tumor models or selected human tumor xenografts (22 , 23 , 40 , 68 , 72, 73, 74, 75, 76) . BMS-214662 also retained good activity when a MDR tumor subline was evaluated for responsiveness and compared historically to the responses obtained with the parental line.
Despite the dramatic effects observed against human tumors, no activity was produced by BMS-214662 against two murine tumor models. We have also tested other FTIs, with structures similar to BMS-214662, against a murine tumor (Madison 109 lung carcinoma) with a known Ras mutation and failed to observe any antitumor effects.3 It is our experience that the complete absence of activity versus commonly used murine tumor models is quite atypical of compounds possessing marked activity against so many different staged human tumors.
The resistance is not completely attributable to inhibition of processing of FT substrates such as Ras in M109 cells. BMS-214662 produces near complete inhibition of Ras processing in M109 cells treated with 500 nM for 48 h (data not shown) in comparison to the same occurring in sensitive HCT-116 cells treated with 100 nM for 24 h (Fig. 2B)
. BMS-214662 exhibited equipotency (H-Ras as the substrate) to the farnesyltransferase enzyme isolated from M109 cells as well as other sensitive cells (IC50, 2–3 nM). When K-Ras was used as the substrate, the enzyme from M109 and MLF cells (both resistant and mouse cells) showed significantly less potency compared with the enzyme from sensitive cells (IC50, 70 nM versus 5–20 nM). However, the enzyme from sensitive PC-3 cells also showed reduced K-Ras potency (IC50, 120 nM). We also compared the FT activity levels in the entire cell panel presented here and found no correlation between enzyme levels and sensitivity, despite the wide range of FT levels across the panel (varied from 2 to 160 fmol/µg protein). Thus, although we did find some differences such as inhibition of FT substrates requiring longer exposure and higher concentrations as well as FT being relatively insensitive with K-Ras as the substrate from M109 cells, it is not clear whether these characteristics are the basis for resistance, particularly given that the doses used in mice produce high micromolar concentrations lasting for 6–12 h.
Our in vitro cytotoxicity results with two murine cell lines are consistent with the relative in vivo antitumor activities (Fig. 5)
. However, it is surprising that HCT-116/VM46 human tumor responded well to BMS-214662 treatment (Table 3)
, although its in vitro cytotoxic potency is only 2-fold different from that of M109 cells (IC50, 0.31 versus 0.68 µM). Thus, although cytotoxicity is a major component of the human tumor regression activity reported here for BMS-214662, the effect of the compound on mouse tumors may be predominantly cytostatic (see also later). Nonetheless, the apparent resistance of mouse tumors is perplexing and remains to be explored further.
BMS-214662 is a potent inhibitor of murine tumor cell growth in vitro (Table 2)
and yet produced no significant growth inhibition in vivo (only 22% growth inhibition was observed toward the end of treatment period in LL). This apparent lack of activity may be a reflection of the intermittent dosing schedule used. Consistent with this interpretation, BMS-214662 and its close analogues did produce 40–60% inhibition of Ras-transformed Rat1 tumor growth in mice with once or twice daily dosing schedules (data not shown). Finally, we also reported that carcinogen-induced skin tumors in mice were susceptible to therapeutic intervention with BMS-214662 (77)
.
The tumor regression and cures described for several human tumor xenografts after a relatively short course of treatment with BMS-214662 raises the question as to what brought about such rapid reduction of tumor volume. Although enzyme inhibitors affecting FT may typically be considered as cytostatic agents or produce regressions in certain specified tumors, the outright destruction of tumors would be unexpected. Although tumor regressions lasting during the dosing period were reported with certain FTIs using Ras transgenic models (22
, 72)
, rapid tumor regressions that last and result in cures have not been described with other FTIs published to date (22
, 23
, 40
, 68
, 72, 73, 74, 75, 76)
. From the in vivo-in vitro tumor excision assay, we determined that there was direct cytotoxicity inflicted on tumor cells in vivo after BMS-214662 treatment. Given that a single dose of 75 mg/kg given as i.v. infusion over 24 h produced 90% cell death in HCT-116 tumors (Fig. 8)
, it is not surprising that repeated and high-dose treatment (175–800 mg/kg) was highly curative.
With further regard to how BMS-214662 exerts is antitumor effects, we demonstrated inhibition of FT and H-Ras processing in the tumors of mice treated with BMS-214662. We also observed increased numbers of apoptotic cells in tumors of treated mice, and the extent of AIs in the tumors correlated well with the extent of tumor regression. We are currently exploring: (a) whether and how FT inhibition is related apoptotic potency; (b) the possibility that BMS-214662 targets a yet to be identified molecule "X" to induce apoptosis; and (c) the relation of FT and "X" to apoptosis and antitumor activity.
On the basis of its efficacy demonstrated in vivo against a variety of human tumors, BMS-214662 was selected for clinical development and is presently in Phase I clinical trials. Thus, BMS-214662 joins three other FTIs, R115777, SCH-66336, and L-778123 that are under various stages of development in the clinic (43) .
|
ACKNOWLEDGMENTS |
|---|
|
FOOTNOTES |
|---|
1 To whom requests for reprints should be addressed, at Oncology Drug Discovery, Department of Signal transduction and Gene Expression, K22-07, Bristol-Myers Squibb Co., P. O. Box 4000, Princeton, NJ 08543. Phone: (609) 252-5832; Fax: (609) 252-6051; E-mail: Veeraswamy.manne{at}bms.com 
2 The abbreviations used are: FT, farnesyltransferase; hFT, human FT; FTI, farnesyltransferase inhibitor; GGTI, geranylgeranyl transferase inhibitor; MDR, multidrug resistant; BMS, Bristol-Myers Squibb Company; ABAE, adult bovine aortic endothelial; LL, Lewis lung; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling; LCK, log cell kill; IC50, compound concentration needed to inhibit cell growth by 50% relative to untreated control cell growth; MEK, mitogen-activated protein kinase kinase; MTD, maximum tolerated dose; MTS, [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfenyl)-2H-tetrazolium, inner salt]; qd, every day; AI, apoptotic index; SAG, soft agar growth.
Received 5/ 2/01. Accepted 8/15/01.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
and TGF /neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis. Clin. Cancer Res., 5: 35-42, 1999.This article has been cited by other articles:
|
|
 |
|
  M. Copland, F. Pellicano, L. Richmond, E. K. Allan, A. Hamilton, F. Y. Lee, R. Weinmann, and T. L. Holyoake BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors Blood, March 1, 2008; 111(5): 2843 - 2853. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. H. Bailey, D. B. Alberti, J. P. Thomas, D. L. Mulkerin, K. A. Binger, M. M. Gottardis, R. E. Martell, and G. Wilding Phase I Trial of Weekly Paclitaxel and BMS-214662 in Patients with Advanced Solid Tumors Clin. Cancer Res., June 15, 2007; 13(12): 3623 - 3629. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Basso, P. Kirschmeier, and W. R. Bishop Thematic review series: Lipid Posttranslational Modifications. Farnesyl transferase inhibitors J. Lipid Res., January 1, 2006; 47(1): 15 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. M.G.M. Appels, J. H. Beijnen, and J. H.M. Schellens Development of Farnesyl Transferase Inhibitors: A Review Oncologist, September 1, 2005; 10(8): 565 - 578. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Bachireddy, P. K. Bendapudi, and D. W. Felsher Getting at MYC through RAS Clin. Cancer Res., June 15, 2005; 11(12): 4278 - 4281. [Full Text] [PDF]
|
|
|
|
 |
|
 C.-L. Gau, J. Kato-Stankiewicz, C. Jiang, S. Miyamoto, L. Guo, and F. Tamanoi Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways Mol. Cancer Ther., June 1, 2005; 4(6): 918 - 926. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Papadimitrakopoulou, S. Agelaki, H. T. Tran, M. Kies, R. Gagel, R. Zinner, E. Kim, G. Ayers, J. Wright, and F. Khuri Phase I Study of the Farnesyltransferase Inhibitor BMS-214662 Given Weekly in Patients with Solid Tumors Clin. Cancer Res., June 1, 2005; 11(11): 4151 - 4159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gomez-Benito, I. Marzo, A. Anel, and J. Naval Farnesyltransferase Inhibitor BMS-214662 Induces Apoptosis in Myeloma Cells through PUMA Up-Regulation, Bax and Bak Activation, and Mcl-1 Elimination Mol. Pharmacol., June 1, 2005; 67(6): 1991 - 1998. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Cortes, S. Faderl, E. Estey, R. Kurzrock, D. Thomas, M. Beran, G. Garcia-Manero, A. Ferrajoli, F. Giles, C. Koller, et al. Phase I Study of BMS-214662, a Farnesyl Transferase Inhibitor in Patients With Acute Leukemias and High-Risk Myelodysplastic Syndromes J. Clin. Oncol., April 20, 2005; 23(12): 2805 - 2812. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Tabernero, F. Rojo, I. Marimon, M. Voi, J. Albanell, M. Guix, F. Vazquez, J. Carulla, M. Cooper, J. Andreu, et al. Phase I Pharmacokinetic and Pharmacodynamic Study of Weekly 1-Hour and 24-Hour Infusion BMS-214662, a Farnesyltransferase Inhibitor, in Patients With Advanced Solid Tumors J. Clin. Oncol., April 10, 2005; 23(11): 2521 - 2533. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. K. Dy, L. M. Bruzek, G. A. Croghan, S. Mandrekar, C. Erlichman, P. Peethambaram, H. C. Pitot, L. J. Hanson, J. M. Reid, A. Furth, et al. A Phase I Trial of the Novel Farnesyl Protein Transferase Inhibitor, BMS-214662, in Combination with Paclitaxel and Carboplatin in Patients with Advanced Cancer Clin. Cancer Res., March 1, 2005; 11(5): 1877 - 1883. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Cesario, A. Catassi, L. Festi, A. Imperatori, A. Pericelli, D. Galetta, S. Margaritora, V. Porziella, V. Cardaci, P. Granone, et al. Farnesyltransferase Inhibitors and Human Malignant Pleural Mesothelioma: A First-Step Comparative Translational Study Clin. Cancer Res., March 1, 2005; 11(5): 2026 - 2037. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Manne, F. Y. F. Lee, D. K. Bol, J. Gullo-Brown, C. R. Fairchild, L. J. Lombardo, R. A. Smykla, G. D. Vite, M.-L. D. Wen, C. Yu, et al. Apoptotic and Cytostatic Farnesyltransferase Inhibitors Have Distinct Pharmacology and Efficacy Profiles in Tumor Models Cancer Res., June 1, 2004; 64(11): 3974 - 3980. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Mackay, R. Hoekstra, F. A. L. M. Eskens, W. J. Loos, D. Crawford, M. Voi, A. Van Vreckem, T. R. J. Evans, and J. Verweij A Phase I Pharmacokinetic and Pharmacodynamic Study of the Farnesyl Transferase Inhibitor BMS-214662 in Combination with Cisplatin in Patients with Advanced Solid Tumors Clin. Cancer Res., April 15, 2004; 10(8): 2636 - 2644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. P. Ryan, J. P. Eder Jr., T. Puchlaski, M. V. Seiden, T. J. Lynch, C. S. Fuchs, P. C. Amrein, D. Sonnichsen, J. G. Supko, and J. W. Clark Phase I Clinical Trial of the Farnesyltransferase Inhibitor BMS-214662 Given as a 1-Hour Intravenous Infusion in Patients with Advanced Solid Tumors Clin. Cancer Res., April 1, 2004; 10(7): 2222 - 2230. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
, Control; 
, BMS- 214662 at 800 mg/kg/administration; •, 500 mg/kg/administration; 127, 300 mg/kg/administration. Fifty % of the mice were cured at the 800 mg/kg/administration level.
